How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
Pharma & Biotech
Pharma & Biotech
Landmark FDA nod gives MSC developers long-awaited quality benchmark for clinical use
The FDA has recognized Tasly’s 3P assay as the first quality control standard for MSCs. Find out what this changes for developers and regulators.
Medical Devices & Diagnostics
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.
Medical Devices & Diagnostics
BioTissue divests surgical and wound care business to BioStem, sharpening focus on ocular regeneration
BioTissue Holdings, Inc. has completed the divestiture of its non-ocular surgical and wound care business to BioStem Technologies, Inc. in a transaction valued at approximately $15 million upfront, with potential earnouts tied to regulatory and commercial milestones. The deal transfers ownership of the Neox and Clarix product lines, along with a seasoned commercial team and